[go: up one dir, main page]

PL1904044T3 - Zastosowanie kombinacji obejmującej L- karnitynę lub alkanoilo-L-karnitynę, rozpuszczalny w tłuszczach benzochinon oraz wielonienasycony kwas tłuszczowy omega-3 do wytwarzania suplementu diety lub leku do leczenia chorób rogówki - Google Patents

Zastosowanie kombinacji obejmującej L- karnitynę lub alkanoilo-L-karnitynę, rozpuszczalny w tłuszczach benzochinon oraz wielonienasycony kwas tłuszczowy omega-3 do wytwarzania suplementu diety lub leku do leczenia chorób rogówki

Info

Publication number
PL1904044T3
PL1904044T3 PL06777532T PL06777532T PL1904044T3 PL 1904044 T3 PL1904044 T3 PL 1904044T3 PL 06777532 T PL06777532 T PL 06777532T PL 06777532 T PL06777532 T PL 06777532T PL 1904044 T3 PL1904044 T3 PL 1904044T3
Authority
PL
Poland
Prior art keywords
carnitine
solubl
benzoquinone
alkanoyl
omega
Prior art date
Application number
PL06777532T
Other languages
English (en)
Inventor
Franco Gaetani
Janos Feher
Original Assignee
Sigma Tau Ind Farmaceuti
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sigma Tau Ind Farmaceuti filed Critical Sigma Tau Ind Farmaceuti
Publication of PL1904044T3 publication Critical patent/PL1904044T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/115—Fatty acids or derivatives thereof; Fats or oils
    • A23L33/12—Fatty acids or derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/221—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having an amino group, e.g. acetylcholine, acetylcarnitine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • Nutrition Science (AREA)
  • Mycology (AREA)
  • Emergency Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
PL06777532T 2005-07-08 2006-06-30 Zastosowanie kombinacji obejmującej L- karnitynę lub alkanoilo-L-karnitynę, rozpuszczalny w tłuszczach benzochinon oraz wielonienasycony kwas tłuszczowy omega-3 do wytwarzania suplementu diety lub leku do leczenia chorób rogówki PL1904044T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP05014812 2005-07-08
PCT/EP2006/063769 WO2007006672A1 (en) 2005-07-08 2006-06-30 Use of a combination comprising l-carnitine or alkanoyl l-carnitine, lipid solubl benzoquinone and omega-3-polyunsaturated fatty acid for the preparation of a dietary supplement or medicament for the treatment of corneal diseases
EP06777532A EP1904044B1 (en) 2005-07-08 2006-06-30 Use of a combination comprising l-carnitine or alkanoyl l-carnitine, lipid solubl benzoquinone and omega-3-polyunsaturated fatty acid for the preparation of a dietary supplement or medicament for the treatment of corneal diseases

Publications (1)

Publication Number Publication Date
PL1904044T3 true PL1904044T3 (pl) 2013-08-30

Family

ID=34937798

Family Applications (1)

Application Number Title Priority Date Filing Date
PL06777532T PL1904044T3 (pl) 2005-07-08 2006-06-30 Zastosowanie kombinacji obejmującej L- karnitynę lub alkanoilo-L-karnitynę, rozpuszczalny w tłuszczach benzochinon oraz wielonienasycony kwas tłuszczowy omega-3 do wytwarzania suplementu diety lub leku do leczenia chorób rogówki

Country Status (19)

Country Link
US (1) US8349317B2 (pl)
EP (1) EP1904044B1 (pl)
JP (1) JP5112308B2 (pl)
KR (1) KR101262076B1 (pl)
CN (1) CN101242818B (pl)
AU (1) AU2006268787B2 (pl)
BR (1) BRPI0613389A2 (pl)
CA (1) CA2611914C (pl)
CY (1) CY1114251T1 (pl)
DK (1) DK1904044T3 (pl)
ES (1) ES2409037T3 (pl)
HR (1) HRP20130319T1 (pl)
MX (1) MX2007016048A (pl)
PL (1) PL1904044T3 (pl)
PT (1) PT1904044E (pl)
RS (1) RS52735B (pl)
SG (1) SG162836A1 (pl)
SI (1) SI1904044T1 (pl)
WO (1) WO2007006672A1 (pl)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8343753B2 (en) 2007-11-01 2013-01-01 Wake Forest University School Of Medicine Compositions, methods, and kits for polyunsaturated fatty acids from microalgae
TWI474817B (zh) * 2008-07-04 2015-03-01 Sigma Tau Ind Farmaceuti 用於預防或治療調節性眼疲勞之化合物類
US20120016027A1 (en) * 2010-07-15 2012-01-19 Brien Holden Vision Institute Composition and Method for Improved Lens Comfort
CN105997973A (zh) * 2010-11-19 2016-10-12 日本水产株式会社 用于角膜上皮病变和/或结膜上皮病变的治疗剂或预防剂
EP2716167A1 (en) * 2012-10-02 2014-04-09 Lunamed AG Non-pharmaceutical composition comprising short chain fatty acids
JP7474598B2 (ja) * 2020-02-03 2024-04-25 小林製薬株式会社 経口組成物
JP7474599B2 (ja) * 2020-02-03 2024-04-25 小林製薬株式会社 経口組成物

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1235153B (it) 1988-11-15 1992-06-22 Sigma Tau Ind Farmaceuti Uso dell'acetil l-carnitina nel trattamento terapeutico della cataratta e composizioni farmaceutiche utili in tale trattamento
IT1277953B1 (it) * 1995-12-21 1997-11-12 Sigma Tau Ind Farmaceuti Composizione farmaceutica contenente l-carnitina o una alcanoil l- carnitina e un acido poliinsaturo della serie 3-omega utile per
IT1299191B1 (it) * 1998-06-23 2000-02-29 Sigma Tau Healthscience Spa Composizione atta a prevenire e trattare l'osteoporosi e le alterazioni legate alla menopausa
IT1307281B1 (it) * 1999-11-25 2001-10-30 Simonelli Giuseppe Uso di ubichinone q10 per il trattamento locale e la prevenzione dipatalogie oftalmologiche secondarie alla terapia fotorefrattiva,
CA2291959A1 (en) * 1999-12-08 2001-06-08 Alex P. Korn A nutriceutical composition of l-carnitine, ubiquinone, n-3 polyunsaturated fatty acids and vitamins specifically formulated at pharmacological doses for the amelioration of the risk factors and symptoms of atherosclerosis-related illnesses
US20040076695A1 (en) 2002-07-08 2004-04-22 Advanced Vision Research EPA and DHA enriched omega-3 supplement for the treatment of dry eye, meibomianitis and xerostomia
WO2004006801A2 (en) * 2002-07-17 2004-01-22 Biosyntrx, Inc. Treatment for dry eye syndrome
US9192586B2 (en) * 2003-03-10 2015-11-24 Zeavision Llc Zeaxanthin formulations with additional ocular-active nutrients, for protecting eye health and treating eye disorders
US20050074443A1 (en) * 2003-10-03 2005-04-07 Treadwell Benjamin V. Methods of attenuating autoimmune disease and compositions useful therefor

Also Published As

Publication number Publication date
CN101242818B (zh) 2011-09-21
CN101242818A (zh) 2008-08-13
BRPI0613389A2 (pt) 2011-01-11
JP2009500374A (ja) 2009-01-08
US8349317B2 (en) 2013-01-08
CA2611914A1 (en) 2007-01-18
US20100034795A1 (en) 2010-02-11
CA2611914C (en) 2013-11-19
PT1904044E (pt) 2013-04-26
ES2409037T3 (es) 2013-06-24
RS52735B (sr) 2013-08-30
EP1904044B1 (en) 2013-03-27
CY1114251T1 (el) 2016-08-31
HRP20130319T1 (hr) 2013-05-31
KR101262076B1 (ko) 2013-05-08
KR20080036077A (ko) 2008-04-24
AU2006268787A1 (en) 2007-01-18
HK1118722A1 (en) 2009-02-20
AU2006268787B2 (en) 2012-02-02
MX2007016048A (es) 2008-03-10
SG162836A1 (en) 2010-07-29
SI1904044T1 (sl) 2013-05-31
WO2007006672A1 (en) 2007-01-18
JP5112308B2 (ja) 2013-01-09
DK1904044T3 (da) 2013-05-13
EP1904044A1 (en) 2008-04-02

Similar Documents

Publication Publication Date Title
GB2428974B (en) Further medical use of a botanical drug or dietary supplement
GB2459809A (en) Fatty acid formulations and methods of use thereof
EP2371853A3 (en) Insulin derivatives or its pharmaceutically acceptable salt, pharmaceutical composition, use of insulin derivative or its pharmaceutically acceptable salt and method of treatment
MX2011008448A (es) Uso de ester etilico del acido eisosapentaenoico para tratar hipertrigliceridemia.
ZA200810756B (en) Enantiomerically pure flavone derivatives for the treatment of poliferative disorders and processes for their preparation
LT1741439T (lt) Tradicinis kiniečių vaistinis preparatas, skirtas gydyti širdies-smegenų kraujagyslių ligas, ir jo gavimo būdas
EP1758595A4 (en) Use of lipid conjugates in the treatment of diseases
WO2008093848A1 (ja) ホスファチジルコリンを含有する炎症マーカー低減組成物
IL196745A (en) Idabanon for use in providing mucosal pathways to treat disease
EP2094281A4 (en) USE OF LIPID CONJUGATES IN THE TREATMENT OF DISEASES OR OCULAR DISORDERS
WO2008149802A1 (ja) アンドログラホリドを有効成分とする抗疲労剤及び経口組成物
IL201438A (en) Use of bipolar trans-carotenoids for pre-treatment and treatment of peripheral vein disease
TW200744574A (en) Use of L-carnitine or of alkanoyl L-carnitines for the preparation of a physiological supplement of medicament for ophthalmic use in the form of eye-drops
CY1114251T1 (el) Χρηση ενος συνδυασμου ο οποιος περιλαμβανει l-kapnitinh ή αλκανοϋλ l-kapnitinh, λιποδιαλυτη βενζοκινονη και ωμεγα-3-πολυακορεστο λιπαρο οξυ για την παρασκευη ενος διαιτητικου συμπληρωματος ή φαρμακου για τη θεραπευτικη αγωγη παθησεων του κερατοειδους
WO2007016679A3 (en) Combination immediate release controlled release levodopa and carbidopa dosage forms
WO2011019735A3 (en) Nutritional supplements
MX2007013301A (es) Agente profilactico/terapeutico para la anormalidades del metabolismo del azucar/lipidos.
ZA200607531B (en) Use of agomelatine in obtaining medicaments intended for the treatment of sleep disorders in the depressed patient
WO2007038596A3 (en) Phytosterol nutritional supplements
EP1592409A4 (en) USE OF EDIBLE ACIDITY IN QUICKLY DISPERSIBLE PHARMACEUTICAL SOLID DOSAGE FORMS
MX2009005503A (es) Uso de l-carnitina para la preparacion de un medicamento en forma de gotas oculares para el tratamiento de enfermedades de la cornea.
PT1742927E (pt) Derivados do ácido butanóico, processos para a sua preparação, composições farmacêuticas que os contêm, e suas aplicações terapêuticas
SI1761257T1 (sl) Uporaba acetil-L-karnitina za pripravo zdravila za zdravljenje nevropatske bolečine pri diabetičnih bolnikih
IL200192A (en) Use of l-cannitin and / or alkonial l-carnitine, or their common pharmaceutical salt, in combination with statin, for the preparation of a drug for the treatment of type 2 diabetes
ATE399474T1 (de) Use of unsaturated fatty acids for the reduction of appetite or food intake